CagriSema explained: Novo Nordisk’s cagrilintide + semaglutide co-formulation, dual amylin/GLP-1 mechanism, REDEFINE phase 3 data showing 22.7% weight loss, comparison to semaglutide and tirzepatide, and what it means for peptide research.
What separates compounding pharmacies from research peptide vendors? This guide covers 503A/503B regulations, quality testing standards, pricing, the FDA crackdown context, and how to evaluate quality in each channel.
A researcher’s comparison of oral vs injectable semaglutide: SNAC absorption technology, bioavailability differences, OASIS trial data, dosing equivalence, and practical research considerations.
A research-based guide to seven peptides with the strongest evidence in longevity biology — Epithalon, GHK-Cu, NAD+, MOTS-c, SS-31, FOXO4-DRI, and Thymosin Alpha-1 — with mechanism breakdowns and evidence ratings.
A research-based breakdown of peptide side effects by category — GLP-1s, GH secretagogues, melanocortins, and tissue repair peptides — plus how to distinguish mechanism-based from contaminant-based reactions.
Follistatin and GDF-8 myostatin propeptide take different approaches to blocking myostatin signalling. This research guide compares their mechanisms, evidence base, and practical considerations for muscle hypertrophy research.
Six peptides have been studied most extensively in post-exercise tissue repair research: BPC-157 for tendon and muscle, TB-500 for systemic cell migration and inflammation, CJC-1295 + Ipamorelin for GH pulses during sleep, MGF for satellite cell activation, IGF-1 LR3 for anabolic signaling, and MOTS-c for mitochondrial recovery. Each targets a different stage of the repair cascade.
Most peptides are destroyed in the gut before they reach the bloodstream. Subcutaneous injection achieves 75–95% bioavailability. Oral semaglutide uses SNAC technology to get ~1%. Semax and Selank were built for nasal delivery. Here’s the science behind why each route works — or doesn’t.
Survodutide pairs GLP-1 with glucagon receptor agonism. Retatrutide adds GIP on top. Both have produced striking liver fat data and are heading toward Phase 3 readouts in 2026–2027. This guide breaks down the receptor profiles, trial programs, and key differences.
A research guide to the peptides most studied for fat loss without muscle loss: Semaglutide, Retatrutide, AOD-9604, Tesamorelin, CJC-1295+Ipamorelin, AICAR, and Follistatin — mechanisms, clinical evidence, and recomposition comparison.
